23rd Jul 2018 14:36
LONDON (Alliance News) - SalvaRx Group PLC said on Monday its subsidiary iOx Therapeutics Ltd has seen a significant delay in manufacturing its lead drug candidate IMM60.
The cancer immunotherapy-focused biotech company noted quality failures in the manufacturing process, which has led to iOx revising its timeline to dosing its first human in clinical trials.
The release of the product required for dosing is now expected to be in late 2019.
"The company is confident that its process is robust and that it will move the programme forward in due course," SalvaRx said in a statement.
Shares in SalvaRx were down 16% at 38.11 pence on Monday.
Related Shares:
SALV.L